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DOI 10.1186/s12883-017-0866-6RESEARCH ARTICLE Open AccessStability and relative validity of the
Neuromuscular Disease Impact Profile
(NMDIP)
Isaäc Bos1* , Jan B.M. Kuks1, Josué Almansa2, Hubertus P.H. Kremer1 and Klaske Wynia1,2Abstract
Background: The aim of this study was to examine the stability and relative validity (RV) of the Neuromuscular
Disease Impact Profile (NMDIP) using criterion-related groups. In a previous study the NMDIP-scales showed good
internal consistency, convergent and discriminant validity. Known-groups analysis showed that the NMDIP discriminates
between categories of extent of limitations.
Methods: A cross-sectional postal survey study was performed on patients diagnosed with a NMD and registered at the
Department of Neurology, University Medical Center Groningen, the Netherlands.
Participants were asked to complete the preliminary NMDIP, the Medical Outcome study Short Form Questionnaire
(SF-36), the World Health Organization Quality Of Life-abbreviation version (WHOQOL-bref), and two generic
domain specific measures: the Groningen Activity Restriction Scale (GARS) and the Impact on Participation and Autonomy
Questionnaire (IPAQ). The variables ‘Extent of Limitations’ and ‘Quality of Life’ were used to create criterion-related groups.
Stability over time was tested using the Wilcoxon Signed Rank Test for paired samples and the intraclass correlation
coefficients for repeated measures. RV was examined by comparing the ability of NMDIP with generic multidimensional
health impact measures, and domain specific measures in discriminating between criterion-related subgroups using the
Kruskal-Wallis H-test.
Results: Response rate was 70% (n = 702). The NMDIP-scales showed sufficient stability over time, and satisfactory or
strong RV. In general, the NMDIP scales performed as well as or better than the concurrent measurement instruments.
Conclusions: The NMDIP proved to be a valid and reliable disease-targeted measure with a broad scope on physical,
psychological and social functioning.
Keywords: Neuromuscular Disease Impact Profile, Relative validity, Test-retest reliability, Stability, Criterion validityBackground
Neuromuscular Diseases (NMDs) may be caused by an ab-
normality of the anterior horn cells, sensory ganglion cells
(neuronopathy), the peripheral nerves (neuropathy), neuro-
muscular junctions (myasthenia), or muscle (myopathy).
Common symptoms and signs of NMD include muscle
weakness, impairment in muscle endurance, involuntary
muscle activity (stiffness, myotonia, cramps, and fascicula-
tions), sensory loss, autonomic dysfunction and impair-
ment in control of voluntary movements. Sensations of* Correspondence: i.bos@umcg.nl
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(http://creativecommons.org/publicdomain/zepain and fatigue are common consequences of muscle and
nerve pathology [1, 2]. Easy to apply NMD-specific reliable
and validated self-report assessment tools are essential for
obtaining insight into the prevalence and severity of the
broad range of patient perceived health-related problems
in NMDs. This is important for research and for clinical
practise as well, in order to narrow the gap between the cli-
nician’s and patient’s view on the actual health situation
and to help to tailor care plans to the patient’s need and
preferences [3]. We therefore developed the disability-
severity Neuromuscular Disease Impact Profile (NMDIP)
based on the ICF-Core set for NMDs, a set of categories
selected from the International Classification of Function-
ing, Disability and Health (ICF) [2, 4].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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components and are divided into eight scales and four
single items. The NMDIP-scales showed moderate to
good Cronbach’s alpha and mean inter-item correlation
coefficients. Convergent and discriminant validity ana-
lysis indicated that the NMDIP measures the impact of
neuromuscular disease on physical, psychological and
social functioning. The NMDIP discriminates between
groups of patients who differ in ‘Extent of limitations’.
The four single items represent the Environmental Fac-
tors component (three items) and one Body Functions
item (Seeing function) [4].
The objective of this study was to further examine the
psychometric properties of the NMDIP and to build on
previous studies on this measurement instrument [2, 4].
We examined its stability over time by assessing the
test-retest reliability of the NMDIP-scales. We further-
more compared the ability of the NMDIP scales to dis-
criminate between criterion related subgroups with this
ability of four established concurrent measurement in-
struments, by assessing the Relative Validity (RV) [5, 6].
The RV coefficient indicates how much more or less




A cross sectional study, using a postal survey, was admin-
istered to patients diagnosed with a NMD who were regis-
tered at the Department of Neurology of the University
Medical Center Groningen, University of Groningen, the
Netherlands. Inclusion criteria for this study were: diagno-
sis with a NMD and representing one of Rowland’s NMD
classification groups: motor-neuron disorders, muscle dis-
orders, junction disorders and peripheral nerve disorders
[7]; being aged 18 or older; being able to read and write in
Dutch; and being able to give informed consent. No exclu-
sion criteria were formulated.
A total of 1003 eligible patients were selected from the
hospital patient records system. To avoid inappropriately
sending the questionnaires, we crosschecked for de-
ceased patients using the national population register.
Patients received information about the study and were
invited to participate.
Respondents completed demographic and disease specific
questions, the NMDIP, two criterion variables to measure
the ‘Extent of Limitations’ and ‘Quality of Life’. Also, con-
current measures were completed: two generic multidi-
mensional health impact measures (the Medical Outcome
study Short Form Questionnaire (SF-36) [8], and the World
Health Organization Quality Of Life-abbreviation version
(WHOQOL-bref) [9], and two generic domain specific
measures the Groningen Activity Restriction Scale (GARS)
[10] and the Impact on Participation and AutonomyQuestionnaire (IPAQ) [11]. To assess stability over time,
the NMDIP was administered on two occasions to patients
who agreed to fill in the questionnaire twice. We, arbitrary,
selected a time frame from eight to 10 weeks to be sure
that patients could not remember their answers on the first
questionnaire, and the likelihood of changes in the health
situation was minimal.
Measurement instruments
The NMDIP includes 36 items and consists of eight
scales and four additional items. The 36 items were divided
over the four ICF components. For the Body Functions
component items and for the Participation component
items scoring options ranged from 0 (no disability) to 4
(complete disability); for the Activities component items
scoring options ranged from 0 (no disability) to 3
(complete disability); and for the Environmental Factors
component items scoring options ranged from 0 (no sup-
port) to 2 (full support) [4]. Item scores were summed into
a scale with higher scores indicating more disability. To
evaluate the RV, we used the ‘Physical Functioning’ con-
struct as represented by the ‘Activities of Moving around’
and ‘Self-care and Domestic Activities’ scales, the ‘Psycho-
logical Functioning’ construct as represented by the ‘Men-
tal Functions and Pain’ scale, and the ‘Social Functioning’
construct as represented by the ‘Participation in Life Situa-
tions’ scale. These scales were selected because items in
these scales are closely associated with the scales in the
concurrent measures.
The SF-36 was selected as a well-known reliable and valid
generic multidimensional health-impact measure used for
NMD [12, 13]. The SF-36 [8] comprises 36 items with eight
functional dimensions. Three scales were used to examine
the RV: ‘Physical Functioning’, ‘Mental Health’ and ‘Social
Functioning’. Item scores were coded, summed and trans-
formed to a score of 0 (worst health) to 100 (best health)
for each scale. The overall Cronbach’s alpha for these scales
was 0.79 in a study of Amyotrophic Lateral Sclerosis pa-
tients [14]. In our previous study the Cronbach’s alpha for
the selected scales ranged from 0.77 to 0.94 [4].
The WHOQOL-bref [9] was selected as a generic meas-
urement instrument for a broad evaluation of quality of
life. It consists of 28 items in four constructs and two sep-
arate questions. Three scales were used to examine the
RV: ‘Physical Health and Autonomy’, ‘Psychological Health’,
and ‘Social Relations’. Item scores from each scale were
coded, summed and transformed to a score of 0 (worst
health) to 20 (best health). The Cronbach’s alpha ranged
from 0.63 to 0.81 in a study of Multiple Sclerosis patients
[15]. In our previous study the Cronbach’s alpha for the
selected scales ranged from 0.60 to 0.84 [4].
The GARS [10] is a domain specific generic measure-
ment instrument for assessing disability in ‘Activities of
daily living’ (ADL) and ‘Instrumental activities of daily
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IADL items. A four-category response format was used,
and ranged from 1 (no problem in performing without
help) to 4 (impossible to perform). The scores were
summed for each subscale. The Cronbach’s alpha ranged
from 0.95 to 0.97 in a study of Multiple Sclerosis
patients [15]. In our previous study the Cronbach’s alpha
ranged from 0.93 to 0.95 [4].
The IPAQ [11, 16] is a domain specific generic meas-
urement instrument for assessing participation. It con-
sists of fifteen items focusing on person-perceived
participation and autonomy. The instrument assesses
two aspects of participation: perceived participation and
the perceived problems with participation. In this study
the perceived participation aspect was used since this
construct is closely associated with the ‘Participation
in Life Situations’ construct in the NMDIP question-
naire. The sub-domains were ‘Autonomy Indoors’,
‘Family Role’, ‘Autonomy Outdoors’, and ‘Social Rela-
tions’. The response options ranged from 1 (very
good) to 5 (very poor). Scores were summed for each
domain. The Cronbach’s alpha ranged from 0.86 to
0.94 in a study of Multiple Sclerosis patients [15]. In
our previous study the Cronbach’s alpha ranged from
0.84 to 0.94 [4].
Criterion variables
Two questions were selected as criterion variables: ‘Extent
of limitations’ and ‘Quality of life’.
To evaluate the ‘Extent of Limitations’ respondents
were asked to answer the question: ‘To what extent are
you limited due to your NMD?’ Responses were on a
ten-point scale ranging from 1 (not limited at all) to 10
(completely limited). Respondents were classified into
one of four groups: Group A with a ‘very low extent of
limitation’ (score 1–2), Group B with a ‘moderate extent
of limitation’ (score 3–5), Group C with a ‘high extent of
limitation’ (score 6–8) and, Group D with a ‘very high
extent of limitation’ (score 9–10).
The second criterion variable for evaluation of quality of
life was one of the two single items adapted from the
WHOQOL-bref. Respondents were asked: ‘How would
you rate your quality of life?’. Response options were:
1 = very poor, 2 = poor, 3 = neither poor nor good, 4 = good
and 5 = very good. Respondents were classified into three
groups: Group A– ‘very poor or poor quality of life’, Group
B– ‘neither poor nor good’, and Group C– ‘good or very
good quality of life’.
Analysis
Descriptive statistics were used to characterize the total
sample and the test-retest sample. Differences between
both samples were examined using the difference in pro-
portions test, the two-sample t-test, and if data are notnormally distributed a non-parametric test for independ-
ent samples were used.
Test-retest reliability or stability over time was ex-
amined using the Wilcoxon Signed Test and the
one-way random intraclass correlation coefficients
(ICCs) [17].
Relative Validity was examined in several steps.
First, the Chi-square was computed for each scale by
calculating the Kruskal-Wallis H-test. Second, the RV
of each scale was computed by dividing each H-
statistic by the H-statistic for the scale with the high-
est H-statistic, and multiplied by one hundred. The
resulting RV-estimate indicates the extent to which a
scale or construct is able to discriminate between two
groups compared to the measure with the highest H-
statistic [18, 19]. Finally, the clinical relevance of the
differences between respondent subgroups, and the
nonparametric effect size (coefficient r) for unrelated
samples, was calculated for statistically significant
group differences (α = 0.05) with post hoc tests (Bon-
ferroni correction) [20]. Effect sizes where estimated
through coefficient r, which was calculated by dividing
the z-statistic (obtained from the Mann-Whitney U
test) by the root of the sample size (n). To interpret
this nonparametric effect sizes (coefficient r), Cohen
suggested the following thresholds: an r of <0.10 indi-
cates a trivial effect, an r of ≥0.10 to <0.24 a small ef-
fect, a r of ≥0.24 to <0.37 a moderate effect, and an
r ≥ 0.37 a large effect. A r ≥ 0.10 reflects a clinically
relevant difference between groups [20, 21].
IBM SPSS statistics version 22 was used.Results
A total of 702 participants (70% response rate) completed
the questionnaires. Of the 202 patients who agreed to
complete the NMDIP twice 185 participants (92% response
rate) actually returned the questionnaire.
The non-respondents from the 1003 eligible patients
did not differ from respondents in terms of gender, but
non-responders were significantly younger than respon-
dents (p-value < 0.001 not in table).
The total sample (n = 702) and the test-retest sample
(n = 185) differed in Age, Years since diagnosis. Partici-
pants in the total sample were older and were diagnosed
more recently with a NMD compared to the test-retest
sample. Also a significant larger proportion of respondents
in the total sample was ‘Retired due to age’ compared to
test-retest sample (p-value = 0.007) (Table 1). Finally the
NMD category distribution differed significantly between
the samples with less patients with Motor-neuron disor-
ders and Muscle disorders and more patients with Periph-
eral nerve disorders in the total sample compared to the
test-retest sample.
Table 1 Patient characteristics of total sample and test-retest sample




Female 350 (50) 105 (57) 0.095^
Male 352 (50) 80 (43) 0.095^
Age 0.024##
Median (IQR) 61 (21) 57 (18)
Range 19–92 19–92
Year since diagnosis 0.003##
Median (IQR) 7 (11) 10 (14)
Range 0–65 1–64
Extent of limitations 0.329##
Median (IQR) 5 (4) 6 (4)
Range 1–10 1–10
Quality of life (WHOQOL-bref) 0.129##
Median (IQR) 4 (1) 4 (1)
Range 1–5 1–5
Relationship status (%)
Relationship (married/partnership) 515 (73) 135 (76) 0.910^
Single (unmarried/widowed/divorced) 186 (27) 45 (24) 0.549^
Educational level (%)
Primary school/vocational training 235 (33) 57 (31) 0.492^
Secondary school/vocational training 270 (38) 81 (44) 0.188^
Higher education /vocational training 161 (23) 37 (20) 0.394^
University 28 (4) 8 (4) 0.837^
Employment status (more answers possible) (%)
Following a training or study 36 (5) 12 (7) 0.468^
Employment (part-time or full time) 173 (25) 43 (23) 0.693^
Voluntary work (part-time or full time) 42 (6) 15 (8) 0.294^
(Partially) retired due to NMD 213 (30) 67 (36) 0.126^
Housewife/househusband 171 (24) 55 (30) 0.136^
Retired due to age 244 (35) 45 (24) 0.007^
NMD category (%)
Motor neuron disorder (MND) 43 (6) 20 (11) 0.027^
Muscle disorder (MD) 154 (22) 69 (37) <0.001^
Junction disorder (JD) 234 (33) 66 (36) 0.549^
Peripheral nerve disorder (PND) 271 (39) 30 (16) <0.001^
^Difference in proportions test, ##Mann-Whitney U test. Interquartile range (IQR) = Q3-Q1
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Wilcoxon Signed Rank Test (Table 2) showed no signifi-
cant score differences between time points for most of
the NMDIP scales, indicating stability over time, except
for the ‘Mental Functions and Pain’ scale. However
this difference was not clinically relevant (ES 0.18,
not shown in table). The ICC of all scales showedsufficient agreement and ranged from 0.79 to 0.97, in-
dicating good stability over time.Criterion-related relative validity
Median scores of patients with a low ‘Extent of limita-
tion’ (Table 3) or very poor or poor ‘Quality of life’ level
Table 2 Test-retest reliability for the NMDIP scales (n = 185)








Median (IQR) Z-statistic p-value*
0 1
Muscle Functions 177 4 (2) 179 4 (2) −2.08 0.037 0.85
Movement Functions 161 2 (3) 153 2 (2) −.006 0.995 0.88
Excretion and Reproductive Functions 135 2 (3) 144 1 (3) −1.00 0.318 0.85
Swallowing and Speech Function 172 0 (2) 180 0 (2) −0.23 0.818 0.91
Mental Functions and Pain 164 4 (4) 162 4 (3) −3.39 0.001 0.90
Activities of Moving around 185 4 (6) 185 4 (6) −1.23 0.219 0.96
Self-care and Domestic Activities 185 3 (9) 185 3 (7) −0.41 0.683 0.97
Participation in Life Situations 180 1 (2) 182 0 (2) −1.70 0.090 0.79
*Wilcoxon Signed Rank Test, 2-tailed. Interquartile range (IQR) = Q3-Q1
Bos et al. BMC Neurology  (2017) 17:87 Page 5 of 8(Table 4) were significantly different in the hypothesized
direction when compared to the next higher group mean.
Extent of limitations
About 16% (n = 110) of the respondents reported ‘low ex-
tent of limitations’ (Group A) due to NMD, while 36%
(n = 250) reported a ‘moderate extent of limitation’ (Group
B), and 39% (n = 270) reported a ‘high extent of limitation’
(Group C). About 8% (n = 58) of the respondents reported
a ‘very high extent of limitations’ (Group D).
Comparisons of the RV coefficients, as summarized in
Table 3, revealed that the NMDIP ‘Activities of Moving
around’ scale and SF-36 ‘Physical Functioning’ scale were
the most valid in discriminating between groups with an
increasing extent of limitation.
We then examined the performance of the NMDIP-
scales in indicating the differences between extreme
groups (A-D) and subgroups (A-B, B-C, C-D) regarding
the physical-, psychological- and social functioning con-
structs, as they relate to similar constructs in the con-
current measurement instruments. Regarding physical
functioning, we found that both NMDIP activity scales
turned out to be the most sensitive (followed by the
‘Muscle Functions’ scale) for measuring differences be-
tween extreme groups and subgroups. However, the per-
formance of the concurrent SF-36 ‘Physical functioning’
scale and both GARS scales were almost identical. Re-
garding the psychological functioning construct we
found that the NMDIP ‘Mental Functions and Pain’ scale
was the best performing scale compared to the SF-36
‘Mental Health’ scale and the WHOQOL-bref ‘Psycho-
logical Health’ scale, showing the highest extreme group
and subgroup differences. Regarding the social function-
ing construct the NMDIP ‘Participation in Life Situa-
tions’ scale performed better than the SF-36 ‘Social
Functioning’ and the WHOQOL-bref ‘Social Relations’
scales, and roughly as well as the same as the compar-
able constructs in the domain-specific IPAQ.In summary, the NMDIP scales performed sufficient to
good in discriminating between (sub) groups with an in-
creasing extent of limitations compared to similar con-
structs in concurrent measures regarding physical
functioning, psychological functioning and social func-
tioning constructs.
Quality of life
Eight percent (n = 53) of the respondents reported poor
or very poor quality of life (Group A), while 25%
(n = 175) experienced their quality of life as neither poor
nor good (Group B) and 67% (n = 474) reported a good
or very good quality of life’ (Group C).
Comparisons of the RV-coefficients, as summarized in
Table 4, revealed that the SF-36 ‘Psychological Health’
scale and IPAQ ‘Autonomy outdoors’ scales were the
most valid in discriminating between groups with differ-
ences in quality of life. The ‘Mental Functions and Pain’
NMDIP scale was the third most valid scale.
When examining the performance of the NMDIP-
scales in indicating the differences between extreme and
subgroups for quality of life, we found about the same
extreme group differences for the physical functioning
scales for all concurrent constructs with moderate Effect
Sizes (ESs). The same goes for the subgroup differences,
although the NMDIP ‘Mental Functions and Pain’ scale,
and the WHOQOL-bref ‘Psychological Health’ scale per-
formed slightly better than the SF-36 ‘Mental Health’
scale. Finally, when examining the social functioning
scales we found that the comparable NMDIP ‘Partici-
pation in Life Situations’ scale performed about as well
as the SF-36 ‘Social Functioning’ scale and the IPAQ
scales with a moderate to large ESs for extreme group
differences. The NMDIP ‘Participation in Life Situa-
tions’ scale also performed better compared to the so-
cial functioning construct of the WHOQOL-bref, the
‘Social Relations’ scale. The same goes for the sub-
group differences.
Table 3 Relative validity of the NMDIP, domain specific and generic measurement instruments compared, using subgroups of





































Chi Square RVb es es es es
NMDIP
Muscle Functions 97 2 (2) 231 3 (2) 263 4 (2) 56 6 (3) 221.3 88 0.44 0.30 0.44 0.78
Movement Functions 92 0 (1) 210 2 (2) 232 3 (2) 49 5 (4) 149.3 59 0.34 0.30 0.29 0.72
Excretion and Reproductive Functions 82 0 (1) 182 1 (2) 194 2 (3) 43 3 (3) 47.1 19 0.16 0.18 - 0.51
Swallowing and Speech Function 107 0 (0) 238 0 (1) 258 0 (1) 55 1 (2) 48.6 19 0.17 0.11 0.18 0.50
Mental Functions and Pain 95 2 (2) 205 4 (3) 237 5 (4) 50 6.5 (5) 128.0 51 0.30 0.29 0.21 0.64
Activities of Moving around 110 0 (2) 250 3 (4) 272 6 (7) 58 13 (9) 251.0 99 0.42 0.39 0.39 0.79
Self-care and Domestic Activities 109 0 (1) 250 2 (3) 272 4 (8) 58 16.5 (14) 219.7 87 0.36 0.35 0.37 0.81
Participation in Life Situations 108 0 (0) 249 0 (1) 271 2 (4) 55 4 (4) 168.5 67 0.24 0.33 0.30 0.76
SF-36
Physical Functioning 109 27 (6) 250 21 (8) 272 16 (7) 58 11 (3) 252.9 100 0.41 0.38 0.43 0.78
Mental Health 110 25 (3) 250 25 (5) 271 24 (6) 58 21.5 (7) 35.2 14 - 0.12 0.14 0.40
Social Functioning 110 10 (1) 250 8 (2) 271 7 (3) 58 5.5 (4) 129.8 51 0.31 0.26 0.22 0.62
WHOQOL-bref
Physical Health and Autonomy 108 3 (1) 244 3 (0) 271 3 (0) 57 3 (1) 68.0 27 0.21 0.19 - 0.47
Psychological Health 106 4 (0) 246 3.5 (0.5) 271 3.5 (1) 57 3 (0) 68.0 27 0.19 0.14 0.25 0.55
Social Relations 104 4 (1) 238 4 (0) 261 4 (1) 55 4 (1) 30.8 12 - 0.14 - 0.35
GARS
Activities of Daily Living 110 11 (1) 250 13 (6) 272 17 (10) 58 27 (17) 213.5 84 0.31 0.35 0.39 0.79
Instrumental Activities of Daily Living 109 7 (2) 250 10 (7) 270 15 (9) 58 24 (5) 215.0 85 0.33 0.35 0.39 0.78
IPAQ
Autonomy Indoors 110 7 (3) 250 13 (6) 272 14 (6) 57 19 (11) 174.3 69 0.37 0.27 0.32 0.75
Family Role 110 8.5 (7) 248 15 (7) 271 18 (7) 58 22 (9) 177.3 70 0.40 0.28 0.22 0.71
Autonomy Outdoors 110 5.5 (4) 249 9 (3) 272 11 (5) 56 14 (4) 238.5 94 0.39 0.40 0.31 0.76
Social Relations 110 9 (6) 250 12 (4) 272 13 (5) 56 13 (4) 87.0 34 0.24 0.23 - 0.52
nmdip, gars, and ipaq: higher scores = more unable to perform activity; sf-36 and WHOQOL-bref scales: higher scores = better quality of life and more able to
perform activity. Interquartile range (IQR) = Q3-Q1. - = not statistically significant. Bonferroni correctiona = 0.0125 (p-value 0.05/4). RV = relative validity,b = score
indicating the relative validity with score 100 related to the highest H-statistic. ES = effect size
Bos et al. BMC Neurology  (2017) 17:87 Page 6 of 8In summary, the NMDIP scales performed well in dis-
criminating between subgroups with differences in qual-
ity of life compared to similar constructs in concurrent
measures concerning the physical functioning, psycho-
logical functioning and social functioning constructs.
Discussion
In this study the NMDIP, that was developed to reflect
the prevalence and severity of a broad range of NMD-
related disabilities [4], showed stability and performed
well in the criterion-related subgroups of NMD-
patients who differed in the extent of limitation and
quality of life.The results of the test-retest reliability analysis were
sufficient indicating stability in the eight NMDIP scales.
Although the results showed a difference for ‘Mental
Functions and Pain’ scale while the effect size was
trivial, the intraclass correlation showed sufficient
agreement for all NMDIP scales between the two
measurement moments.
In general, the NMDIP scales performed well in dis-
criminating between relevant subgroups with increasing
extent of limitation. This was the case for constructs
evaluating physical, psychological, and social function-
ing. The NMDIP scales showed satisfactory relative val-
idity and moderate to strong ESs indicating the strength
Table 4 Relative validity of the NMDIP, domain specific and generic measurement instruments compared, using subgroups of
Quality of Life (n = 702)
Group A (n = 53)
Very poor or poor
QoL
Group B (n = 175)
Neither poor nor
good QoL
Group C (n = 474)


















Muscle Functions 52 5 (2) 167 4 (2) 439 3 (2) 81.4 50 0.34 0.23 0.35
Movement Functions 46 4 (3) 148 3 (2) 400 2 (3) 83.8 51 0.30 0.27 0.35
Excretion and Reproductive Functions 36 3 (5) 129 2 (2) 344 1 (2) 40.6 25 0.21 0.22 0.25
Swallowing and Speech Function 49 2 (3) 162 0 (1) 458 0 (1) 43.6 27 0.26 0.14 0.27
Mental Functions and Pain 45 8 (4) 147 6 (4) 405 3 (4) 147.7 90 0.28 0.42 0.40
Activities of Moving around 53 10 (8) 175 4 (6) 474 3 (5) 75.2 46 0.36 0.19 0.35
Self-care and Domestic Activities 53 10 (13) 175 3 (8) 473 2 (4) 79.9 49 0.32 0.22 0.33
Participation in Life Situations 52 4.5 (5) 175 2 (4) 468 0 (2) 103.7 63 0.32 0.26 0.39
SF-36
Physical Functioning 53 12 (4) 175 17 (8) 473 21 (10) 85.7 52 0.38 0.23 0.34
Mental Health 53 20 (6) 175 22 (6) 473 25 (4) 132.5 81 0.27 0.35 0.38
Social Functioning 53 5 (3) 175 7 (2) 473 9 (2) 138.3 84 0.31 0.36 0.38
WHOQOL-bref
Physical Health and Autonomy 53 3 (5) 173 3 (0) 466 3 (0) 117.7 72 0.21 0.41 0.34
Psychological Health 53 3 (0) 173 3 (1) 466 4 (0) 163.8 100 0.31 0.40 0.41
Social Relations 50 3 (1) 170 4 (1) 450 4 (0) 61.3 37 - 0.25 0.25
GARS
Activities of Daily Living 53 26 (16) 175 17 (10) 474 13 (7) 80.6 49 0.37 0.20 0.35
Instrumental Activities of Daily Living 52 22 (12) 175 15 (9) 472 11 (9) 82.8 51 0.34 0.23 0.33
IPAQ
Autonomy Indoors 53 19 (9) 175 14 (5) 473 12 (7) 109.6 67 0.32 0.29 0.36
Family Role 53 24 (8) 175 20 (8) 471 15 (8) 127.6 78 0.28 0.34 0.37
Autonomy Outdoors 53 15 (4) 174 11 (5) 471 8 (5) 157.6 96 0.42 0.35 0.43
Social Relations 53 15 (6) 175 13 (3) 472 11 (5) 134.1 82 0.26 0.35 0.37
nmdip, gars, IPAQ scales: higher scores = lower quality of life, sf-36, and WHOQOL-bref scales: higher scores = higher quality of life. Interquartile range (IQR) = Q3-
Q1. - = not statistically significant. Bonferroni correctiona = 0.02 (p-value 0.05/3). RV relative validity.b = score indicating the relative validity with score 100 related
to the highest H-statistic. ES effect size
Bos et al. BMC Neurology  (2017) 17:87 Page 7 of 8of the differences between subgroups. The NMDIP showed
satisfactory performance in discriminating between rele-
vant subgroups with decreasing Quality of Life. This was
the case for constructs evaluating physical, psychological
and social functioning.
Strength of this study is the inclusion of a large popula-
tion of patients diagnosed with a NMD. Some potential
study limitations should be mentioned. First, RV was ex-
amined as criterion-related validity value in this study. Be-
cause of the absence of a widely accepted criterion
measure we chose to use self-report measures, which
turned out to be a useful method. Secondly, the (relatively)
small group sizes for ‘very high extent of limitations’
(Group D) and ‘very poor or poor quality of life’ (Group
A) might have a negative impact on detecting groupdifferences, though the difference between these sub-
groups and the adjacent groups showed sufficient ESs.
The results in this study permit us to recommend that
researchers consider Relative Validity as a useful method
to select a valid and ‘with caution’ a sensitive measure,
especially when data from longitudinal studies or inter-
vention studies are lacking. At the same time, we want
to stress that RV is not a substitute for the sensitivity-to-
change test. The findings in this study cannot be gener-
alized to longitudinal studies. We recommend further
research to evaluate the sensitivity to change of the
NMDIP scales.
Furthermore generic health measures have some disad-
vantages against disease-specific health measures in ad-
dressing topics of a particular relevance to patients with a
Bos et al. BMC Neurology  (2017) 17:87 Page 8 of 8specific disease. Therefore it is recommended that the in-
dividual items in a scale be examined to estimate the suit-
ability of the scale for a particular patient population [13].
Conclusions
The results in this study confirmed the stability of the
NMDIP over time, and showed good relative validity com-
pared to generic QOL and domain-specific measures. In
combination with the findings in our previous study [4],
the NMDIP proved to be a valid and reliable disease-
targeted measure with a broad scope on physical, psycho-
logical and social functioning. Further research should
examine the responsiveness of the NMDIP scales.
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